SBIR Phase II: Vasoreactive Perfused in Vitro Vascular Network

SBIR II 期：体外血管网络血管反应性灌注

• 批准号: 2127102
• 负责人: Gail Hatfield
• 金额: $ 98.8万
• 依托单位: ARACARI BIOSCIENCES, INC.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2127102&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Vasoreactive; Perfused

This award is funded in whole or in part under the American Rescue Plan Act of 2021 (Public Law 117-2).The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is to improve clinical outcomes related to cardiovascular side effects of various treatments. It is currently not possible to test this activity on cells in a petri dish, and mice are not an accurate model for predicting these outcomes in human clinical trials. Rodent lifespans, metabolism and responses to drugs are often very different from those of humans. This project advances a pre-clinical drug screening platform, leading to the development of better and safer drugs.This Small Business Innovation Research (SBIR) Phase II project improves accurate pre-clinical screening of new pharmaceutical compounds that may trigger unwanted effects on vascular tone and blood pressure. Both hypertension and hypotension can have immediate and long-term life-threatening effects on patients, and are almost always disqualifying for further development of a new drug. As a result, there is a need for improved, human cell-based models to screen vasoactive drugs for human patients. This project advances a platform to accurately mimic physiologically-relevant vasoactivity.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该奖项的全部或部分资金来自《2021年美国救援计划法案》(公法117-2)。这一小型企业创新研究(SBIR)第二阶段项目的更广泛影响/商业潜力是改善与各种治疗的心血管副作用相关的临床结果。目前还不可能在培养皿中的细胞上测试这种活性，小鼠也不是在人类临床试验中预测这些结果的准确模型。啮齿动物的寿命、新陈代谢和对药物的反应往往与人类截然不同。该项目推进了临床前药物筛选平台，导致更好和更安全的药物的开发。这个小企业创新研究(SBIR)第二阶段项目提高了对可能会对血管紧张性和血压产生有害影响的新药物化合物的准确临床前筛选。高血压和低血压都可能对患者产生直接和长期的生命威胁，而且几乎总是取消了进一步开发新药的资格。因此，需要改进的、基于人类细胞的模型来为人类患者筛选血管活性药物。这个项目提供了一个准确模拟生理相关血管活动的平台。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。